You are here: Industry Insights > cancer

News List

IriSys Doubles Contract with NCI for Mfg. Clinical Trial Materials contractpharma
April 21, 2017
The contract is for development and production of new therapeutic agents for use in clinical trials supported by NCI
Targovax initiates clinical immunotherapy trial to treat RAS-mutated cancer europeanpharmaceuticalreview
April 21, 2017
Targovax, a clinical stage company focused on developing immune-oncology therapies to target solid tumours, has recruited the first patient in an exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent RAS-mutated rectal cancer sche
Cancer Research UK, CPF and NCI partner to develop tests to analyse RAS inhibitors pharmaceutical-technology
April 20, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) National Cancer Institute (NCI), US, have ...
Roche's drug scores expanded FDA indication in advanced bladder cancer pharmafile
April 19, 2017
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded ...
CR UK, CRT Pioneer Fund and the NCI link on RAS pharmatimes
April 19, 2017
Cancer Research UK and the Cancer Research Technology Pioneer Fund (CPF) are committing £2.5 million in collaboration...
BMS links with Apexigen to test cancer immunotherapy combo pharmatimes
April 14, 2017
Bristol-Myers Squibb and Apexigen are to test a combination of Opdivo and the latter’s investigational compound APX005M in patients with advanced solid tumours.
NICE’s draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says pharmaceutical-technology
April 14, 2017
US-based Bristol-Myers Squibb has confirmed that the National Institute for Health and Care Excellence (NICE) has issued draft guidance that ignores recommendation of investigational cancer immunotherapy Opdivo (nivolumab).
Cancer can be diagnosed by Google's artificial intelligence biospectrumasia
April 14, 2017
The system is able to scan samples to determine whether or not tissues are cancerous
SMC u-turn backs Roche’s Kadcyla for breast cancer pharmatimes
April 12, 2017
Women in Scotland will be among the first in the UK to have routine NHS access to Roche’s breast cancer drug Kadcyla ...
NICE turns down BMS' Opdivo for head and neck cancer pharmafile
April 11, 2017
Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head and neck cancer treatment.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page